MedTrace Logo

Tofacitinib Registry of Patients With Ulcerative Colitis in Germany

NCT04032756 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2021-10-08

No results posted yet for this study

Summary

This registry on Tofacitinib and biologics (anti-integrin/anti-TNF) in the treatment of ulcerative colitis (UC) patients in Germany will extend the prospective documentation of safety issues and efficacy in induction and maintenance therapy of Tofacitinib (Xeljanz®) in addition to other biologics used in Germany with a particular interest in predictors of long-term responses and favorable disease outcome or to predict severe side effects caused by therapy with Januskinase(JAK)- inhibitors/biologics.

Conditions

  • Colitis, Ulcerative
  • Biologics
  • Tofacitiniib
  • Chronic Inflammatory Small Bowel Disease
  • Bowel Diseases, Inflammatory
  • Bowel Disease
  • CED

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Ced Service GmbH

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-01
Primary Completion
2020-11-15
Completion
2020-11-15

Countries

  • Germany

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04032756 on ClinicalTrials.gov